Acceleron Presents Results of Sotatercept in P-II PULSAR Trial for the Treatment of Pulmonary Arterial Hypertension, Published in NEJM

 Acceleron Presents Results of Sotatercept in P-II PULSAR Trial for the Treatment of Pulmonary Arterial Hypertension, Published in NEJM

Acceleron Presents Results of Sotatercept in P-II PULSAR Trial for the Treatment of Pulmonary Arterial Hypertension, Published in NEJM

Shots:

  • The P-II PULSAR trial involves assessing Sotatercept (0.3 mg/kg or 0.3 mg/kg, SC, q3w) vs PBO in 106 patients in a ratio (3:3:4) with PAH. The results were published in NEJM
  • The results of the P-II PULSAR study that demonstrated sotatercept has the potential to provide benefits to patients with PAH on top of currently available therapies. The 1EPs @ 24week trial, showed improvement in pulmonary vascular resistance and 2EPs showed mean improvement from a baseline of six-min walk distance, was well-tolerated
  • The company is planning two additional P-III studies of HYPERION and ZENITH in newly diagnosed patients and with WHO functional class IV disease to treat PAH. Additionally, the P-III STELLAR trial is ongoing

Click here to­ read full press release/ article | Ref: BusinessWire | Image: BusinessWire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post